Search clinical trials for: Refractory MBC

Total 10604 results

Thames Valley Air Ambulance

Recruiting

VectOr ChAnge defibriLlatIon in Refractory Shockable rhyThms (VOCALIST)

Ventricular Fibrillation | Ventricular Tachycardia | Cardiac Arrest

United Kingdom
Gustave Roussy, Cancer Campus, Grand Paris
Daiichi Sankyo, Inc.

Recruiting

Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer (ICARUS-BREAST)

Metastatic Breast Cancer

France
Imperial College London
Medical Research Council; Imperial College Healthcare Nissen Fund

Recruiting

Coronary Sinus Reducer Objective Impact on Symptoms, MRI Ischaemia and Microvascular Resistance (ORBITA-COSMIC)

Refractory Angina

United Kingdom
NovalGen Ltd.

Recruiting

First in Human Study of NVG-111 in Relapsed/Refractory ROR1+ Malignancies

Follicular Lymphoma | Mantle Cell Lymphoma | Diffuse Large B Cell Lymphoma | Non-small Cell Lung Cancer (NSCLC) | Small Lymphocytic Lymphoma | Malignant Melanoma | Chronic Lymphocytic Leukaemia

United Kingdom
Joel Neal
Nektar Therapeutics

Completed

Phase 2 Etirinotecan Pegol in Refractory Brain Metastases & Advanced Lung Cancer / Metastatic Breast Cancer

Tumors Metastatic to Brain | Stage IV Non-small Cell Lung Cancer (NSCLC) | Recurrent Non-small Cell Lung Cancer (NSCLC) | Extensive-stage Small Cell Lung Cancer (SCLC) | Recurrent Small Cell Lung Cancer (SCLC) | Metastatic Breast Cancer (mBC)

United States
Eastern Cooperative Oncology Group
National Cancer Institute (NCI); Eli Lilly and Company; Kanisa Pharmaceuticals

Completed

Daunorubicin & Cytarabine +/- Zosuquidar inTreating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or Refractory Anemia

Myelodysplastic Syndromes | Leukemia

United States, Israel
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

Erythropoietin (EPO)+/- Filgrastim (G-CSF) vs. Supportive Therapy Alone for Patients With Myelodysplastic Syndromes

Myelodysplastic Syndromes | Anemia

United States
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

Comparison of Three Treatment Regimens in Treating Patients With Relapsed or Refractory Acute Myelogenous Leukemia

Leukemia

United States, Puerto Rico, South Africa
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

Epoetin Alfa With or Without Dexamethasone in Treating Fatigue and Anemia in Patients With Hormone-Refractory Prostate Cancer

Fatigue | Anemia | Prostate Cancer

United States
Eastern Cooperative Oncology Group
National Cancer Institute (NCI); European Organisation for Research and Treatment... and other collaborators

Completed

Combination Chemotherapy With or Without PSC 833 in Treating Patients With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States, Canada
Queen Mary University of London
CVRx, Inc.

Terminated

UK Registry for Baroreflex Activation Therapy (UK-BAT)

Hypertension, Resistant to Conventional Therapy | Baroreflex Failure Syndrome

United Kingdom
Fudan University

Completed

500mg Fulvestrant Versus Everolimus Plus Exemestane in MBC Patients Refractory to Previous AI

Breast Cancer

China
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement

Pain | Urinary Complications | Breast Adenocarcinoma | DS Stage I Plasma Cell Myeloma | DS Stage II Plasma Cell Myeloma | Metastatic Malignant Neoplasm to the Bone | Musculoskeletal Complication

United States, Puerto Rico
Celgene

Completed

CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma

Multiple Myeloma

United States, Canada
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

American Ginseng in Treating Patients With Fatigue Caused by Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia | Fatigue | Chronic Myeloproliferative Disorders | Unspecified Adult Solid Tumor, Protocol Specific | Multiple Myeloma and Plasma Cell Neoplasm | Precancerous Condition | Lymphoproliferative Disorder | Myelodysplastic/Myeloproliferative Neoplasms

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Topotecan in Treating Patients With Myelodysplastic Syndrome

Myelodysplastic Syndromes | Leukemia

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer

Lung Cancer

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Karenitecin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer

Lung Cancer

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma

Lymphoma

United States, Puerto Rico
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Combination Chemotherapy in Treating Patients With Relapsed or Refractory Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma

Lymphoma

United States, Puerto Rico
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Combination Chemotherapy in Treating Patients With Recurrent or Refractory Small Cell Lung Cancer

Lung Cancer

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Gemtuzumab Ozogamicin and High-Dose Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Leukemia

United States, Puerto Rico
Consorzio Oncotech
Clinical Research Technology S.r.l.

Unknown

Safety and QoL of Trastuzumab With Lapatinib or Chemiotherapy in MBC and HER2+ Patients Refractory to Anti HER2 Therapies

Metastatic Breast Cancer

Italy
Celgene Corporation
Prologue Research International

Completed

Safety And Efficacy Of Lenalidomide In Patients With Relapsed Or Refractory Aggressive Non-Hodgkin's Lymphoma (NHL)

Non-Hodgkins Lymphoma

United States
University of Nottingham
National Institute for Health Research, United Kingdom

Unknown

Trial of the Clinical and Cost Effectiveness of a Specialist Expert Mood Disorder Team for Refractory Unipolar Depressive Disorder

Chronic Unipolar Depressive Disorder

United Kingdom
Southwest Oncology Group
National Cancer Institute (NCI)

Terminated

S9922 Combination Chemo Plus Filgrastim With or Without Thalidomide in Refractory Multiple Myeloma

Multiple Myeloma

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S0010 506U78 in Treating Patients With Recurrent or Refractory Acute Lymphocytic Leukemia

Leukemia

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S9920 Busulfan Compared With Cyclophosphamide in Patients Undergoing Total-Body Irradiation Plus Peripheral Stem Cell Transplantation for Advanced Myelodysplastic Syndrome or Related Acute Myeloid Leukemia

Myelodysplastic Syndromes | Leukemia

United States, Canada
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S0020 Immunosuppressive Therapy in Treating Patients With Myelodysplastic Syndrome

Myelodysplastic Syndromes | Leukemia

United States
Children's Oncology Group
National Cancer Institute (NCI)

Completed

hu14.18-Interleukin-2 Fusion Protein in Treating Young Patients With Recurrent or Refractory Neuroblastoma

Neuroblastoma

United States, Canada
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Biological Therapy in Treating Children With Refractory or Recurrent Neuroblastoma or Other Tumors

Sarcoma | Unspecified Childhood Solid Tumor, Protocol Specific | Neuroblastoma | Melanoma (Skin)

United States, Canada, Australia
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Docetaxel in Treating Children With Relapsed or Refractory Acute Lymphoblastic or Acute Myeloid Leukemia

Leukemia

United States, Canada, Australia, Switzerland, Puerto Rico, Netherlands, New Zealand
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Recurrent or Refractory Hodgkin's or Non-Hodgkin's Lymphoma

Lymphoma

United States, Canada, Puerto Rico, Australia, Netherlands, New Zealand, Switzerland
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Development of Strategies to Increase Enrollment in Clinical Trials for Children With Cancer

Sarcoma | Lymphoma | Unspecified Childhood Solid Tumor, Protocol Specific | Leukemia | Ovarian Cancer | Brain and Central Nervous System Tumors | Neuroblastoma | Liver Cancer | Psychosocial Effects of Cancer and Its Treatment | Extragonadal Germ Cell Tumor | Childhood Germ Cell Tumor

United States, Puerto Rico, Canada, Switzerland
University of South Florida
National Cancer Institute (NCI)

Completed

Cyproheptadine and Megestrol in Preventing Weight Loss in Children With Cachexia Caused By Cancer or Cancer Treatment

Lymphoma | Unspecified Childhood Solid Tumor, Protocol Specific | Myelodysplastic Syndromes | Leukemia | Brain Tumor | Cachexia | Myelodysplastic/Myeloproliferative Diseases | Central Nervous System Tumors

United States, Canada, Puerto Rico
Celgene Corporation
Prologue Research International

Completed

Lenalidomide (Revlimid®, CC-5013) in Subjects With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma

Non-Hodgkins Lymphoma

United States, Canada
Southwest Oncology Group
National Cancer Institute (NCI)

Terminated

S0025 Irinotecan in Treating Patients With Refractory Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer

United States, Canada
Gynecologic Oncology Group
National Cancer Institute (NCI); Eastern Cooperative Oncology Group

Completed

Ifosfamide With or Without Paclitaxel in Treating Patients With Advanced, Refractory, or Recurrent Cancer of the Uterus

Sarcoma

United States
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Chemotherapy in Treating Children With Down Syndrome and Myeloproliferative Disorder, Acute Myelogenous Leukemia, or Myelodysplastic Syndrome

Myelodysplastic Syndromes | Leukemia | Myelodysplastic/Myeloproliferative Neoplasms

United States, Canada, Puerto Rico, Australia, Netherlands, New Zealand, Switzerland
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

Bortezomib in Treating Patients With Recurrent or Refractory Extensive-Stage Small Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy

Lung Cancer

Canada, United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Oxaliplatin in Treating Patients With Recurrent or Refractory Ovarian Epithelial Cancer or Primary Peritoneal Cancer That Has Not Responded to Platinum- Based Chemotherapy

Ovarian Cancer | Primary Peritoneal Cavity Cancer

United States, Canada
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Oxaliplatin in Treating Patients With Recurrent or Refractory Cervical Cancer

Cervical Cancer

United States, Canada
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

Arsenic Trioxide in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia

Leukemia

United States, Puerto Rico, South Africa
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Aminocamptothecin in Treating Patients With Recurrent or Refractory Ovarian Epithelial Cancer or Primary Cancer of the Peritoneum

Ovarian Cancer | Primary Peritoneal Cavity Cancer

United States, Canada
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Paclitaxel in Treating Patients With Advanced, Refractory, or Recurrent Cervical or Vaginal Cancer

Cervical Cancer | Vaginal Cancer

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Combination Chemotherapy in Treating Patients With Recurrent or Refractory Cervical Cancer

Cervical Cancer

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Terminated

Docetaxel in Treating Patients With Recurrent or Refractory Ovarian or Primary Peritoneal Cancer

Ovarian Cancer | Primary Peritoneal Cavity Cancer

United States, Canada
Southwest Oncology Group
National Cancer Institute (NCI)

Terminated

S0019 Combination Chemotherapy With or Without Rituximab in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Lymphoma

United States
National Cancer Institute (NCI)

Completed

Chemotherapy in Treating Children With Recurrent or Refractory Sarcomas

Sarcoma

United States, Canada, Puerto Rico, Australia, Netherlands, New Zealand, Switzerland

Search clinical trials for: Refractory MBC

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kuwait

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations